ATE399151T1 - 2-ethyl und 2-ethyliden-19-nor-vitamin d- verbindungen - Google Patents

2-ethyl und 2-ethyliden-19-nor-vitamin d- verbindungen

Info

Publication number: ATE399151T1
Authority: AT; Austria
Prior art keywords: compounds; vitamin; activity; ethyl; ethylide
Prior art date: 2000-05-31

Application number

AT01939792T

Other languages

English (en)

Inventor

Hector Deluca

Rafal Sicinski

Original Assignee

Wisconsin Alumni Res Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-31

Filing date

2001-05-31

Publication date

2008-07-15

2001-05-31 Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found

2008-07-15 Application granted granted Critical

2008-07-15 Publication of ATE399151T1 publication Critical patent/ATE399151T1/de

Links

-1 2-ETHYL Chemical class 0.000 title 1
230000000694 effects Effects 0.000 abstract 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 2
229910052791 calcium Inorganic materials 0.000 abstract 2
239000011575 calcium Substances 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
PKFBWEUIKKCWEW-WEZTXPJVSA-N (1r,3r)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol Chemical group C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 PKFBWEUIKKCWEW-WEZTXPJVSA-N 0.000 abstract 1
206010065687 Bone loss Diseases 0.000 abstract 1
208000029725 Metabolic bone disease Diseases 0.000 abstract 1
210000000988 bone and bone Anatomy 0.000 abstract 1
230000024245 cell differentiation Effects 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1
230000001483 mobilizing effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Neurology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT01939792T 2000-05-31 2001-05-31 2-ethyl und 2-ethyliden-19-nor-vitamin d- verbindungen ATE399151T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US20819900P	2000-05-31	2000-05-31

Publications (1)

Publication Number	Publication Date
ATE399151T1 true ATE399151T1 (de)	2008-07-15

Family

ID=22773624

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01939792T ATE399151T1 (de)	2000-05-31	2001-05-31	2-ethyl und 2-ethyliden-19-nor-vitamin d- verbindungen

Country Status (15)

Country	Link
US (5)	US6806262B2 (de)
EP (1)	EP1286962B1 (de)
JP (1)	JP4022141B2 (de)
AT (1)	ATE399151T1 (de)
AU (2)	AU2001265272B2 (de)
BR (1)	BR0111173A (de)
CA (1)	CA2410880C (de)
DE (1)	DE60134549D1 (de)
DK (1)	DK1286962T3 (de)
ES (1)	ES2309069T3 (de)
IL (1)	IL152942A (de)
MX (1)	MXPA02011820A (de)
NZ (1)	NZ522909A (de)
PT (1)	PT1286962E (de)
WO (1)	WO2001092221A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6392071B1 (en) *	1997-03-17	2002-05-21	Wisconsin Alumni: Research Foundation	26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
WO2001016099A1 (fr) *	1999-08-27	2001-03-08	Chugai Seiyaku Kabushiki Kaisha	DÉRIVÉS DE VITAMINE D AYANT DES SUBSTITUANTS À LA POSITION 2$g(a)
US20030018017A1 (en) *	2001-01-25	2003-01-23	Deluca Hector F.	Method of treatment of type I diabetes
BR0307896A (pt) *	2002-03-29	2004-12-07	Wisconsin Alumni Res Found	Método de produção de 1(alfa)-hidroxi-2-metileno-19-nor-homopregnacalcif erol
US6846811B2 (en) *	2002-04-22	2005-01-25	Wisconsin Alumni Research Foundation	(20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
EP1559708A4 (de) *	2002-10-10	2006-07-19	Wisconsin Alumni Res Found	2,2-disubstituiertes 1a,25-dihydroxy-19-norvitamin-d-derivat
WO2004067504A1 (ja) *	2003-01-31	2004-08-12	Chugai Seiyaku Kabushiki Kaisha	２位置換ビタミンｄ誘導体
WO2004076468A1 (ja)	2003-02-25	2004-09-10	Kobe Tennenbutsu Kagaku Kabushiki Kaisha	ビタミンｄ誘導体を合成するための新規な中間体
GB0305332D0 (en) *	2003-03-10	2003-04-09	Leuven K U Res & Dev	Biological evaluation of novel vitamin D analogues
BRPI0409194A (pt) *	2003-04-10	2006-04-11	Wisconsin Alumni Res Found	compostos, composição farmacêutica e método de tratamento de doença metabólica do osso, da psorìase, da leucemia, cáncer do cólon, cáncer da mama, cáncer da pele ou cáncer da próstata, de doença auto-imune, de doença inflamatória do intestino e de aumento da resistência do osso
MXPA06000060A (es) *	2003-07-03	2006-04-07	Wisconsin Alumni Res Found	2-metilen-19-nor-20(s)-25-metil-1alfa-hidroxicalciferol y sus usos.
AU2004266706B2 (en) *	2003-08-20	2009-07-30	Wisconsin Alumni Research Foundation	2-methylene-19-nor-vitamin D2 compounds
NZ545393A (en) *	2003-09-19	2009-10-30	Wisconsin Alumni Res Found	2-Alkylidene-19-nor-vitamin D derivatives for the treatment of osteopenia or male osteoporosis
WO2005027928A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	2-alkylidene-19-nor-vit amin d derivatives for the treatment of hypocalcemic tetany or hyproparathyroidism
WO2005027914A1 (en) *	2003-09-19	2005-03-31	Pfizer Products Inc.	2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
US7214670B2 (en) *	2003-09-24	2007-05-08	Wisconsin Alumni Research Foundation	Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings
US7704980B2 (en) *	2003-10-08	2010-04-27	Wisconsin Alumni Research Foundation	Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US8404667B2 (en) *	2006-12-29	2013-03-26	Wisconsin Alumni Research Foundation	Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
US7713951B2 (en) *	2004-04-09	2010-05-11	Wisconsin Alumni Research Foundation	2-alkylidene-18,19-dinor-vitamin D compounds
CA2586679A1 (en)	2004-11-12	2006-05-18	Bioxell Spa	Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
CA2588412A1 (en) *	2004-11-22	2006-06-01	Wisconsin Alumni Research Foundation	2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
AU2005309804B9 (en) *	2004-11-22	2011-12-08	Wisconsin Alumni Research Foundation	2alpha-methyl-19-nor-(20S)-1alpha-hydroxy-bishomopregnacalciferol and its uses
JP5161582B2 (ja) *	2004-11-22	2013-03-13	ウィスコンシン・アルムニ・リサーチ・ファウンデーション	１７，２０（ｚ）−デヒドロビタミンｄ類似体およびそれらの使用
ATE467614T1 (de) *	2004-11-22	2010-05-15	Wisconsin Alumni Res Found	2-methylen-19,26,27-trinor-(20s)-1-alpha- hydroxyvitamin d3 and dessen verwendungen
JP2008520689A (ja)	2004-11-22	2008-06-19	ウィスコンシン・アルムニ・リサーチ・ファウンデーション	１９，２６，２７−トリノル−（２０Ｓ）−１α−ヒドロキシビタミンＤ３の２α−メチルおよび２β−メチル類似体およびそれらの使用
CA2605727A1 (en) *	2005-05-03	2006-11-09	Wisconsin Alumni Research Foundation	19,26,27-trinor-1.alpha.,25-dihydroxyvitamin d3 compounds
US7803789B2 (en) *	2006-02-02	2010-09-28	Wisconsin Alumni Research Foundation	Vitamin D analog—RAK, methods and uses thereof
US7528122B2 (en) *	2006-02-02	2009-05-05	Wisconsin Alumni Research Foundation	Vitamin D analog—NEL, methods and uses thereof
US20090281340A1 (en) *	2006-04-05	2009-11-12	Deluca Hector F	1alpha-hydroxy-2-(3'-hydroxypropylidene)-19-nor-vitamin d compounds and methods of making and treatment thereof
EP2010483A2 (de)	2006-04-05	2009-01-07	Wisconsin Alumni Research Foundation	1.alpha.-hydroxy-2-(3'-hydroxypropyliden)-19-nor-vitamin-d-verbindungen sowie verfahren zu ihrer herstellung und verwendung
MX2008012671A (es) *	2006-04-06	2008-10-15	Wisconsin Alumni Res Found	Analogos 1 a,25-dihidroxi- 19, 26,27-trinor vitamina d 2-sustituidos y sus usos.
US7648973B2 (en) *	2006-04-06	2010-01-19	Wisconsin Alumni Research Foundation	2-methylene-1α,25-dihydroxy-19,21-dinorvitamin D3 analogs and uses thereof
JP2009533483A (ja) *	2006-04-06	2009-09-17	ウイスコンシンアラムニリサーチファンデーション	２−メチレン−１α，２５−ジヒドロキシ−１８，１９，２１−トリノルビタミンＤ３およびその使用
MX2009003241A (es) *	2006-09-28	2009-05-05	Wisconsin Alumni Res Found	Analogos de 2-metilen-(20r,25s)-19,27-dinor-(22e)-vitamina d.
ATE552238T1 (de) *	2006-09-28	2012-04-15	Wisconsin Alumni Res Found	2-methylen-(20s,25s)-19,27-dinor-(22e)-vitamin- - analoga
US7893043B2 (en) *	2008-07-10	2011-02-22	Wisconsin Alumni Research Foundation	2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US7888339B2 (en) *	2008-07-10	2011-02-15	Wisconsin Alumni Research Foundation	2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
US8222236B2 (en) *	2008-07-10	2012-07-17	Wisconsin Alumni Research Foundation	2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
JP5931845B2 (ja) *	2010-03-23	2016-06-08	ウイスコンシンアラムニリサーチファンデーション	２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー
AU2011232633B2 (en) *	2010-03-23	2014-05-29	Wisconsin Alumni Research Foundation	(20S)-2-methylene-19-nor-22-dimethyl-1alpha,25- dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22- dimethyl-1alpha,25-hydroxyvitamin D3
US8664206B2 (en)	2010-03-23	2014-03-04	Wisconsin Alumni Research Foundation	Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666634A (en)	1984-12-05	1987-05-19	Chugai Seiyaku Kabushiki Kaisha	vitamin D3 derivatives having a substituent at 2-position
US5246925A (en)	1989-03-09	1993-09-21	Wisconsin Alumni Research Foundation	19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en)	1989-03-09	1994-12-20	Hector F. Deluca	19-nor-vitamin d compounds
NZ232734A (en)	1989-03-09	1991-11-26	Wisconsin Alumni Res Found	19-nor vitamin d derivatives and pharmaceutical compositions
DE69130497T2 (de)	1990-09-07	1999-04-22	Wisconsin Alumni Research Foundation, Madison, Wis.	Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
US5086191A (en)	1991-05-28	1992-02-04	Wisconsin Alumni Research Foundation	Intermediates for the synthesis of 19-nor vitamin D compounds
AU650751B2 (en)	1991-05-28	1994-06-30	Wisconsin Alumni Research Foundation	Novel synthesis of 19-nor vitamin D compounds
ZA924811B (en)	1991-06-28	1993-12-29	Endorecherche Inc	Controlled release systems and low dose androgens
DE69400495T2 (de)	1993-04-05	1997-04-30	Wisconsin Alumni Res Found	19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
US5565589A (en)	1993-11-03	1996-10-15	Wisconsin Alumni Research Foundation	17-formyl-5,6-trans-vitamin D compounds
US5428029A (en)	1993-11-24	1995-06-27	Hoffmann-La Roche Inc.	Vitamin D3 fluorinated analogs
WO1996001811A1 (en)	1994-07-11	1996-01-25	The Johns-Hopkins University	2-substituted 1,25-dihydroxyvitamin d3 derivatives
EP0793649B1 (de)	1994-11-21	1999-02-03	Wisconsin Alumni Research Foundation	18,19-dinor-vitamin-d-derivate
US5877168A (en) *	1995-02-10	1999-03-02	Chugai Seiyaku Kabushiki Kaisha	Vitamin D derivative with substituent at the 2β-position
CA2175881A1 (en)	1995-05-09	1996-11-10	Andrzej Kutner	Vitamin d compounds and methods of preparing these compounds
ATE289199T1 (de)	1995-06-06	2005-03-15	Merck & Co Inc	Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
US5945410A (en) *	1997-03-17	1999-08-31	Wisconsin Alumni Research Foundation	2-alkyl-19-nor-vitamin D compounds
US5843928A (en) *	1997-03-17	1998-12-01	Wisconsin Alumni Research Foundation	2-alkylidene-19-nor-vitamin D compounds

2001
- 2001-05-31 US US09/871,227 patent/US6806262B2/en not_active Expired - Lifetime
- 2001-05-31 MX MXPA02011820A patent/MXPA02011820A/es active IP Right Grant
- 2001-05-31 DE DE60134549T patent/DE60134549D1/de not_active Expired - Lifetime
- 2001-05-31 AT AT01939792T patent/ATE399151T1/de active
- 2001-05-31 IL IL152942A patent/IL152942A/en not_active IP Right Cessation
- 2001-05-31 EP EP01939792A patent/EP1286962B1/de not_active Expired - Lifetime
- 2001-05-31 PT PT01939792T patent/PT1286962E/pt unknown
- 2001-05-31 AU AU2001265272A patent/AU2001265272B2/en not_active Ceased
- 2001-05-31 DK DK01939792T patent/DK1286962T3/da active
- 2001-05-31 CA CA002410880A patent/CA2410880C/en not_active Expired - Fee Related
- 2001-05-31 JP JP2002500836A patent/JP4022141B2/ja not_active Expired - Lifetime
- 2001-05-31 NZ NZ522909A patent/NZ522909A/en not_active IP Right Cessation
- 2001-05-31 WO PCT/US2001/017662 patent/WO2001092221A1/en not_active Ceased
- 2001-05-31 BR BR0111173-6A patent/BR0111173A/pt not_active Application Discontinuation
- 2001-05-31 ES ES01939792T patent/ES2309069T3/es not_active Expired - Lifetime
- 2001-05-31 AU AU6527201A patent/AU6527201A/xx active Pending
2004
- 2004-10-01 US US10/957,483 patent/US6992074B2/en not_active Expired - Lifetime
2005
- 2005-07-28 US US11/191,791 patent/US7141558B2/en not_active Expired - Lifetime
2006
- 2006-11-22 US US11/603,721 patent/US7300925B2/en not_active Expired - Lifetime
2007
- 2007-08-16 US US11/839,586 patent/US7468361B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6806262B2 (en)	2004-10-19
ES2309069T3 (es)	2008-12-16
IL152942A0 (en)	2003-06-24
IL152942A (en)	2007-09-20
CA2410880A1 (en)	2001-12-06
PT1286962E (pt)	2008-07-30
BR0111173A (pt)	2003-04-29
US7141558B2 (en)	2006-11-28
DK1286962T3 (da)	2008-10-06
JP2004501114A (ja)	2004-01-15
US20050043281A1 (en)	2005-02-24
DE60134549D1 (de)	2008-08-07
AU2001265272B2 (en)	2006-08-17
US7468361B2 (en)	2008-12-23
JP4022141B2 (ja)	2007-12-12
US20080032956A1 (en)	2008-02-07
EP1286962B1 (de)	2008-06-25
US6992074B2 (en)	2006-01-31
EP1286962A1 (de)	2003-03-05
WO2001092221A1 (en)	2001-12-06
US7300925B2 (en)	2007-11-27
US20030013691A1 (en)	2003-01-16
AU6527201A (en)	2001-12-11
NZ522909A (en)	2004-09-24
MXPA02011820A (es)	2003-04-10
CA2410880C (en)	2009-03-03
US20050282789A1 (en)	2005-12-22
US20070088008A1 (en)	2007-04-19

Legal Events

Date

Code

Title

Description

2008-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1286962

Country of ref document: EP

Publication	Publication Date	Title
DE60134549D1 (de)	2008-08-07	2-ethyl und 2-ethyliden-19-nor-vitamin d-verbindungen
AR008853A1 (es)	2000-02-23	Nuevos compuestos farmaceuticamente activos, su uso en la fabricacion de medicamentos, metodo de tratamiento, composicion farmaceutica, compuestosintermediarios y proceso para la fabricacion de dichos compuestos
NZ514574A (en)	2004-02-27	Novel method of treatment
HUP0000558A3 (en)	2000-12-28	Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
AR039985A1 (es)	2005-03-09	Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima
ES2191192T3 (es)	2003-09-01	Tienopirimidinas.
ATE219363T1 (de)	2002-07-15	Lösliche prodrugs von paclitaxel
AR024441A1 (es)	2002-10-02	Agonistas del receptor a2a n-pirazol, composiciones farmaceuticas y el uso de los mismos para preparar un medicamento.
TR200102817T2 (tr)	2002-05-21	Antiinflamatuar ajanlar olarak faydalı bileşikler
CR7420A (es)	2006-02-06	Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12
EA200400881A1 (ru)	2005-02-24	Азаарилпиперазины
ATE308327T1 (de)	2005-11-15	Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
JPS55136229A (en)	1980-10-23	Adjustment of bone metabolism in warm-blooded animal and drug for it
DE69507714D1 (de)	1999-03-18	18,19-dinor-vitamin-d-derivate
SV2002000235A (es)	2002-06-13	Composiciones farmaceuticas que comprenden valdecoxib
ATE537834T1 (de)	2012-01-15	2-methylen-19-nor-vitamin d2-verbindungen
ES2155621T3 (es)	2001-05-16	Derivados azo del acido 5-aminosalicilico para el tratamiento de la enfermedad inflamatoria intestinal.
DE60015508T2 (de)	2005-04-21	C-16 ungesätigte fp-selektive prostaglandin analoge
EP1524264A3 (de)	2010-01-20	2-Ethyliden-19-Nor-Vitamin D-Verbindungen
AU2001284657B2 (en)	2006-01-19	Use of vitamin d derivatives as bone resorption inhibitors
WO2005056520A8 (en)	2005-09-15	Somatostatin receptor subtype 1 (sstr1) active compounds and their use in therapy
DE60006379D1 (de)	2003-12-11	Vitamin d-analogen und ihre pharmazeutische verwendung
RU2001131557A (ru)	2003-09-27	Аналоги витамина D и их фармацевтическое использование
Panebianco et al.	1997	Use of disphosphonates in the treatment of osteoporosis in thyroidectomized patients on levothyroxin replacement therapy
NO974651L (no)	1997-12-02	Biologisk aktive ureidoderivater som er nyttige i behandlingen av multippel sklerose